The US Department of Health and Human Services (HHS) announced termination of 22 contracts totaling nearly $500 million for mRNA vaccine development under BARDA, reflecting a significant shift away from mRNA pandemic preparedness efforts. Secretary Robert F. Kennedy Jr. cited ineffective protection against respiratory infections as rationale, despite extensive clinical data affirming mRNA vaccine efficacy during Covid-19. The move has elicited sharp criticism from experts who warn it undermines pandemic readiness and innovation in mRNA technologies, including applications in cancer vaccines and genetic diseases. The policy change introduces uncertainty in ongoing mRNA R&D and potential ramifications for biotech investment and public health.